




































































Table 1: Three Most Commonly Used Cervical Cancer Screening Methods 
     
Method Test Description Sensitivity Specificity Requirements 




Cervical cells are collected, 
prepared on a slide, 
stained, read and reported 
47-62% 60-95% Multiple medical 
personnel, laboratory 
infrastructure, extensive 
training and education, 
quality assurance 
     
Visual 
screening  
Referred to as visual 
inspection with acetic acid 
(VIA), direct visual 
inspection (DVI), acetic 
acid test (AAT), or 
cervicoscopy. Visual 
inspection of cervix after 
application of 3-5% acetic 
acid with the naked eye 
using a bright light. Test 
results are immediately 
available.   
29-96% 49-98% Regular and consistent 
quality assurance, short 
period of training 
 Visual inspection with 
Lugol's iodine (VILI) 
method involves visual 
inspection of the cervix 
after application of Lugol's 
iodine.  Test results are 
immediately available.   
44-92% 50-90% Regular and consistent 
quality assurance, short 
period of training 
     
HPV testing Cervical cells are collected 
and analyzed using 
polymerase chain reaction 
(PCR)-based method for 
presence of HPV DNA. 
66-100% 62-96% Multiple personnel, 
technical and 
infrastructure 
     
Source: Sankaranarayanan 2006     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Table 2: Prevalence of Cervical HPV 
Infection in South American Countries 






    
Argentina 995 20.1 16, 18 
Bolivia no data 
Brazil 5582 14.1 16, 18 
Chile 913 11.2 16, 31 
Colombia 2882 15.9 16, 18 




Guyana**** 1423 19.3 18 
Paraguay 91 19.8 16, 18 
Peru 4894 7.5 16, 18 
Suriname no data 
Uruguay no data 
Venezuela no data 
    
*HPV prevalence in women with normal 
cytology 
**two most prevalent types detected in 
cervical cancer 
***16 most prevalent, 52/58/59 all second 
in prevalence 
****18 most prevalent, 16/31/39 all 
second in prevalence 
 
Sources: Castellasgue et al. 2007; Brown et al. 2008; 





Table 3: Cervical Cancer Screening 
     
Country Screening Method Program Participation Rate Assessment Method 
     
Argentina Pap (Murillo et al. 2008) organized at provincial level, screening offered to 
women 35-64 years every three years (IARC 
2005) 
(Buenos Aires) 33.6% had undergone Pap testing during 
year preceding survey, 35.8% during past 2 years, 17.4% 
more than 3 years earlier, 13.2% had never had Pap test 
(Eluf-Neto & Nascimento 2001)                                                                                                   
(National) 51.6% for women >18 during past 2 years 
(Murillo et al. 2008) 
survey of women voluntarily 
enrolled in breast cancer 
screening program 
(Sankaranarayanan, Budukh &
Rajkumar 2001) and national 
survey (Cervical Cancer Action 
Coalition 2010) 
Brazil Pap (Murillo et al. 2008) large, national program offers free screening to 
women 25-59 years every three years since 1998 
(Murillo et al. 2008) 
(Sao Paulo) 41.3% had undergone Pap testing during year 
preceding survey, 60.8% during past 3 years, 68.9% at 
least once during their lives (Eluf-Neto & Nascimento 2001)                                                                          
(National) ranging from 64.8% to 68.7% during past 3 
years (Murillo et al. 2008) 
probability sampling 
(Sankaranarayanan, Budukh & 
Rajkumar 2001) and national 
survey (Cervical Cancer Action 
Coalition 2010) 
Bolivia Pap (Bingham et al. 
2003) 
screening free to women 25 to 49 years every 
three years in government facilities since 1988, 
reorganized in 1998 (Bingham et al. 2003; Murillo 
et al. 2008) 
  
Chile Pap (Suarez & Prieto 
2006) 
organized national screening program offers 
screening to women 25-64 years every three 
years since 1987, reorganized in 1994, under 
central supervision of Ministry of Health (Murillo 
et al. 2008; Suarez & Prieto 2006; Arrossi et al. 
2008; Roa et al. 2009) 
(Public Health System) 67% of women 35-64 years, 68% 
of women 25-64 years (screening interval not specified) 
(Suarez & Prieto 2006)                                                                         
(National) ranging from 51.4% for women >15 years to 
66.0% for women 25-64 years during past 3 years (Murillo 
et al. 2008) 
not specified (Suarez & Prieto 
2006) and national survey 
(Murillo et al. 2008) 
Colombia Pap (Murillo et al. 2008) women 25-69 years screened every three years 
since 1991, reorganized in 2000 (Murillo et al. 
2008) 
(National) 50.6% of women 25-69 years during past year 
(Murillo et al. 2008) 
national survey (Murillo et al. 
2008) 
Ecuador Pap (Agurto et al. 2004) screening provided by NGO is free, but limited to 
women living in and around Quito, recent efforts 
to extend coverage to women 35-59 years every 
five years   (Agurto et al. 2004; IARC 2005) 
(National) 31.0% of women 15-49 years screened during 
past 2 years (Murillo et al. 2008) 
national survey (Murillo et al. 
2008) 
French Guiana no organized program   
Guyana  no organized program   
Paraguay Pap (Murillo et al. 2008) women 25-69 years screened at health care 
centers and hospitals every three years since 
2002 (Murillo et al. 2008) 
(National) 73.2% of women 15-44 years during past 2 
years and 45.4% of women 18-69 years during past 3 
years (Murillo et al. 2008) 
national survey (Murillo et al. 
2008) 
Peru VIA with Pap (Murillo et 
al. 2008; Bingham et al. 
2003) 
national plan with mobile campaigns offer 
screening to women 30-49 years every three 
years since 1998 (reported by IARC to include 
women 25-59 every two years) (Murillo et al. 
2008; Bingham et al. 2003; Paz Soldan et al. 
2008) 
(Urban) ranges from 7-42.9% in certain Peruvian cities 
(screening interval not specified) (Paz Soldan et al. 2008) 
(National) 22.7% for women 15-49 years during past year 
(Murillo et al. 2008) 
survey as part of STI prevention 
trial (Paz Soldan et al. 2008) and 
national survey (Murillo et al. 
2008) 
Suriname  no organized program   
Uruguay Pap (Murillo et al. 2008) opportunistic screening offered by appointment 
since 1994 (Murillo et al. 2008) 
(National) 55.2% for women 18-69 years during past 3 
years (Murillo et al. 2008) 
national survey (Murillo et al. 
2008) 
Venezuela Pap (Murillo et al. 2008; 
Ferlay et al, 2008) 
screening is free to women 25-64 years every 
three years since 1996 (Murillo et al. 2008; 





















Table 4: Incidence and Mortality of Cervical Cancer in South America  
vs. Other Geographic Regions 














       
World** 529828 275128 15.8 15.3 8.2 7.8 
Developing regions 453321 241969 16.7 17.8 8.9 9.8 
Developed regions 76507 33159 12.1 9.0 5.2 3.2 
South America 47881 21836 24.6 24.1 11.2 10.8 
Argentina 3996 1809 19.7 17.5 8.9 7.4 
Bolivia 1422 638 29.3 36.4 13.1 16.7 
Brazil 24562 11055 25.2 24.5 11.4 10.9 
Chile 1478 721 17.4 14.4 8.5 6.6 
Colombia 4736 2154 20.7 21.5 9.4 10.0 
Ecuador 1666 832 24.8 27.1 12.4 13.3 
French Guiana 27 10 24.5 29.1 9.1 11.7 
Guyana 161 74 43.3 44.7 19.9 20.5 
Paraguay 864 407 28.0 35.0 13.2 16.6 
Peru 4446 2098 30.9 34.5 14.6 16.3 
Suriname 66 27 25.7 27.2 10.5 11.1 
Uruguay 348 159 20.1 16.5 9.2 6.8 
Venezuela 4116 1853 29.4 31.4 13.2 14.4 
       
*ASR: Age-standardized rate, per 100,000 women per year 
**All countries combined     





Table 5: Ranking of Cervical Cancer Incidence and Mortality                                                                             
to Other Cancers in South America* vs. Other Geographic Regions 
 
 Incidence Mortality 
Region All women Women 15-44 years All women Women 15-44 years 
     
World 3rd 2nd 4th 2nd 
Developing regions 2nd 2nd 2nd 2nd 
Developed regions 10th 3rd 10th 2nd 
South America 2nd 2nd 2nd 1st 
Argentina 3rd 2nd 5th 2nd 
Bolivia 1st 1st 1st 1st 
Brazil 2nd 2nd 2nd 1st 
Chile 3rd 2nd 6th 1st 
Colombia 2nd 1st 1st 1st 
Ecuador 2nd 1st 2nd 1st 
French Guiana 2nd 1st 2nd 1st 
Guyana 1st 1st 1st 1st 
Paraguay 2nd 1st 1st 1st 
Peru 1st 1st 2nd 1st 
Suriname 2nd 2nd 2nd 1st 
Uruguay 3rd 2nd 6th 2nd 
Venezuela 2nd 1st 1st 1st 
 
*Ranking is based on crude incidence and 
mortality rates    
Source: IARC, GLOBOCAN 2008    
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